Suggested Dosing
6-15g/d PO
Decoction used topically
Next:
Suggested Uses
Hemostatic (internal or topical use)
Primary hepatic carcinoma
Efficacy
Decrease tumor size & neovascularization in hepatic cancer
Previous
Next:
Adverse Effects
Frequency Not Defined
Not specified
Previous
Next:
Warnings
Contraindications
Hypersensitivity
Previous
Next:
Pregnancy & Lactation
Pregnancy Category: N/A
Lactation: N/A
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Previous
Next:
Pharmacology
Metabolism: N/A
Excretion: N/A
Mechanism of Action
Astringent, stops blood flow
Promotes arterial embolization in hepatic cancer
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
